Companies in #Placental-Derived Cell Therapy
Found 1 company operating in this sector.
Celularity is a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies and regenerative-medicine products, including the Cenplacel-L point-of-care cellular therapeutic being deployed in regenerative-medicine programs and a portfolio of natural-killer (NK) and T-cell oncology candidates. The company received a Nasdaq notice in May 2026 for delayed filing of its Q1 2026 Form 10-Q and is operating under a 60-day cure-plan window from that notice. Celularity completed a $30M NexGel biomaterials out-license in June 2026 alongside new product-availability partnerships in regenerative medicine.